Adaptive Biotechnologies (NASDAQ:ADPT) COO Julie Rubinstein Sells 19,060 Shares of Stock

Posted by Linda Flegge on Apr 22nd, 2026

Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) COO Julie Rubinstein sold 19,060 shares of the company’s stock in a transaction that occurred on Monday, April 20th. The shares were sold at an average price of $14.55, for a total value of $277,323.00. Following the transaction, the chief operating officer directly owned 399,484 shares of the company’s stock, valued at $5,812,492.20. The trade was a 4.55% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Julie Rubinstein also recently made the following trade(s):

On Tuesday, April 21st, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.66, for a total value of $453,595.06.
On Thursday, April 16th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.18, for a total value of $270,270.80.
On Monday, April 13th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.15, for a total value of $250,639.00.
On Friday, April 10th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $12.77, for a total value of $243,396.20.
On Tuesday, April 7th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.56, for a total value of $258,453.60.
On Wednesday, April 8th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.83, for a total value of $458,855.03.
On Wednesday, April 1st, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.45, for a total value of $275,417.00.
On Monday, March 23rd, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.83, for a total value of $263,599.80.
On Friday, March 20th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.37, for a total value of $254,832.20.
On Wednesday, March 18th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.18, for a total value of $251,210.80.

Adaptive Biotechnologies Stock Performance

ADPT stock opened at $14.21 on Wednesday. Adaptive Biotechnologies Corporation has a fifty-two week low of $6.90 and a fifty-two week high of $20.76. The business’s 50 day moving average price is $14.61 and its two-hundred day moving average price is $16.00. The company has a market capitalization of $2.19 billion, a price-to-earnings ratio of -35.52 and a beta of 2.29.

Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last posted its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The firm had revenue of $71.68 million for the quarter, compared to the consensus estimate of $59.38 million. During the same quarter in the prior year, the business earned ($0.23) EPS. The business’s revenue for the quarter was up 51.0% on a year-over-year basis. Sell-side analysts forecast that Adaptive Biotechnologies Corporation will post -0.5 earnings per share for the current year.

Institutional Trading of Adaptive Biotechnologies

Institutional investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd purchased a new stake in Adaptive Biotechnologies during the 4th quarter valued at $28,000. Sound Income Strategies LLC purchased a new stake in Adaptive Biotechnologies during the 3rd quarter valued at $30,000. EverSource Wealth Advisors LLC boosted its stake in Adaptive Biotechnologies by 197.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after purchasing an additional 1,565 shares during the last quarter. Assetmark Inc. boosted its stake in Adaptive Biotechnologies by 867.9% during the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after purchasing an additional 2,708 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. purchased a new stake in Adaptive Biotechnologies during the 4th quarter valued at $51,000. 99.17% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently weighed in on ADPT. JPMorgan Chase & Co. raised their price objective on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Friday, February 6th. Guggenheim raised their price objective on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a “buy” rating in a research report on Monday, January 26th. TD Cowen reaffirmed a “buy” rating on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Wall Street Zen lowered Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Finally, Piper Sandler set a $21.00 price objective on Adaptive Biotechnologies in a research report on Friday, February 6th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Adaptive Biotechnologies has an average rating of “Moderate Buy” and a consensus price target of $18.25.

Get Our Latest Report on Adaptive Biotechnologies

About Adaptive Biotechnologies

(Get Free Report)

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.